Canada Markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
290.08-1.84 (-0.63%)
At close: 04:00PM EST
289.01 -1.07 (-0.37%)
After hours: 07:28PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close291.92
Open292.36
Bid279.00 x 800
Ask290.66 x 2200
Day's Range289.94 - 295.89
52 Week Range187.16 - 311.88
Volume894,286
Avg. Volume1,228,142
Market Cap42.611B
Beta (5Y Monthly)0.17
PE Ratio (TTM)15.04
EPS (TTM)19.29
Earnings DateFeb 01, 2023 - Feb 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est295.44
  • Zacks

    Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

    Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.

  • Reuters

    UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

    Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The application to the EMA was based on results from a late-stage study that showed the drug slowed down the rate of cognitive decline in patients with early Alzheimer's by 27%, compared with a placebo. Eisai has also filed for approval of the drug in Japan.

  • GlobeNewswire

    Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

    TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of